QQ客服 官方微博 反馈留言

	Targeting chemotherapy of choriocarcinoma by using a CSA-binding peptide coated Targeting chemotherapy of choriocarcinoma by using a CSA-binding peptide coatednanoparticles loaded with doxorubicin
	Xiujun FAN; Baozhen Zhang; Pengfei Zhao; Mingbin Zheng; Gugang Cheng; Dan Li; Lintao Cai; Jian Zhang; Shoujun Li
	2016
会议名称	Systems Biology of Reproduction SSR 49th Annual Meeting
会议地点	美国圣地亚哥
英文摘要	Choriocarcinoma was the first treated cancer by chemotherapy with high success rate about 70% in severe condition, which is relative high rate compare to other type of cancers. However, it still requires high dose systemic chemo-drug delivery, which is harmful to other healthy tissue and organs. To targeting only the choriocarcinoma cells without effect or minimal effect on other normal cell types, we made a choriocarcinoma cell targeting chemo-nanoparticle (CSA-DNPs), by using a CSA binding peptide, which is specific binding to the CSA expressed only in the trophoblast cells, to coat a doxorubicin (DOX) loaded PEG nanoparticles (DNPs). Free DOX, DNPs and DNPs coated with a peptide with random sequence of the same amino acids of CSA binding peptide (S-DNPs) were used as control groups. The produced nanoparticles was with a sphere shape and diameters around 80nm (CSA-DNPs), 70nm (S-DNPs) and 50nm (DNPs). Meantime, the CSA-DNPs could specifically bind to choriocarcinoma cells-JEG3 both in vitro and in vivo as less as 30 minutes with a higher DOX delivery efficiency compare to the controls. The CSA-DNPs entering JEG3 cells through endocytosis and accumulated in the lysosome, where the DOX content in the nanoparticles were released into the cells and kill the tumor cells. In vivo choriocarcinoma models were created by subcutaneous injection and systemic IV injection of JEG3 cells (carrying a firefly luciferase transgene, JEG3-Fluc) in the nude mice, and the treatments were started 2days post the JEG3 cells implantation in all the groups. In the subcutaneous models, the tumor volume reached more than 1cm3 in the controls (Free DOX, DNPs, and S-DNPs) in about 16 to 18 days; and in the systemic model, the tumor were grown in the lungs, brain, kidneys, liver, ovaries, and uteri observed by bioluminescence imaging in the controls groups (Free DOX, DNPs, and S-DNPs) in 16 days. However, no tumor growth was observed in the CSA-DNPs group in both the models. By in vivo bioluminescent imaging analysis, we found the photons emitted from the JEG3-Fluc cells at the end of treatment were significantly lower then the photons emitted at the beginning of the treatment. These results indicated that our newly made CSA-DNPs could specifically target and effectively inhibit the choriocarcinoma cells growth and eliminate existed choriocarcinoma cells. Our results provided an alternate targeting treatment method for choriocarcinoma, and proofs for new targeting drugs development for choriocarcinoma therapies. This work is supported by Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases (2013A061401013)
收录类别	其他
语种	英语
内容类型	会议论文
源URL	[http://ir.siat.ac.cn:8080/handle/172644/10825]
专题	深圳先进技术研究院_医药所
作者单位	2016
推荐引用方式 GB/T 7714	Xiujun FAN,Baozhen Zhang,Pengfei Zhao,et al. Targeting chemotherapy of choriocarcinoma by using a CSA-binding peptide coated Targeting chemotherapy of choriocarcinoma by using a CSA-binding peptide coatednanoparticles loaded with doxorubicin[C]. 见:Systems Biology of Reproduction SSR 49th Annual Meeting. 美国圣地亚哥.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。